2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2722

Cyclic Phosphatidic Acid (CPA) Suppresses Expression of Cartilage Degrading Enzymes Such As MMP-3, MMP-13 and Adamts-4 in Inflammatory Synovial Fibroblasts and Articular Chondrocytes Induced By IL-1 Beta and/or TNF ALFA
Abstract Number: 1818

Cyclophosphamide and Cumulative Steroid Dose Associated with Higher Risk of Infections in Patients with Lupus Nephritis
Abstract Number: 2926

Cytochrome P450 Polymorphisms on Blood Hydroxychloroquine Levels in Patients with Systemic Lupus Erythematosus
Abstract Number: 3

Cytokine Production Patterns in Osteoporosis Suggest a Pro-Inflammatory Bias
Abstract Number: 2465

Cytokine Profile Comparison of Monogenic and Complex Conditions with Interferon-Regulated Gene Signatures in Chronic Atypical Neutrophilic Dermatosis with Lipodsytrophy and Elevated Temperature (CANDLE), SAVI, Aicardi-Goutieres Syndrome, JDM, and SLE
Abstract Number: 2812

Cytokine Secretion By Peripheral Blood Mononuclear Cells in Patients with Axial Spondyloarthritis and the Effect of Thymoquinone on Cytokine Profile
Abstract Number: 1357

Cytomegalovirus (CMV) Infections in Patients with Rheumatic Diseases: Experience of a Referral Center
Abstract Number: 1937

Dalazatide (ShK-186), a First-in-Class Blocker of Kv1.3 Potassium Channel on Effector Memory T Cells: Safety, Tolerability and Proof of Concept of Immunomodulation in Patients with Active Plaque Psoriasis
Abstract Number: 3031

Dalazatide (ShK-186), a Kv1.3 Channel Inhibitor That Targets Effector Memory T Cells: Ex Vivo Studies in Pediatric Systemic Lupus Erythematosus
Abstract Number: 1944

Dalazatide Modulates CD4+ Effector Memory T-Cell Activity of Patients with Granulomatosis with Polyangiitis in Vitro
Abstract Number: 731

Damage and Mortality in SLE: Cluster Analysis of Patients from SLE Registry from the Spanish Society for Rheumatology (RELESSER)
Abstract Number: 2156

Damage Assessment in Giant Cell Arteritis
Abstract Number: 3068

Damage Assessment in Takayasu’s Arteritis
Abstract Number: 876

Damage Develops Early and Is Common in Children with Chronic Systemic Vasculitis
Abstract Number: 2623

DAS28-ESR and DAS28-CRP Are Not Exchangeable in Daily Clinical Practice: Data from a Large Outpatient Cohort

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].